实体器官移植中的间充质干细胞（MiSOT）第四次会议：首次临床试验的经验教训。
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.
机构信息
Transplantation and Nephrology, Erasmus MC, Rotterdam, The Netherlands.
出版信息
Transplantation. 2013 Aug 15;96(3):234-8. doi: 10.1097/TP.0b013e318298f9fa.
Abstract
The Fourth Expert Meeting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took place in Barcelona on October 19 and 20, 2012. This meeting focused on the translation of preclinical data into early clinical settings. This position paper highlights the main topics explored on the safety and efficacy of mesenchymal stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (proper timing, concomitant immunossupression, source and immunogenicity of mesenchymal stem cells, and oncogenicity) that have been addressed and will be followed up by the MiSOT Consortium in future studies.
摘要
2012 年 10 月 19 日至 20 日，实体器官移植间充质干细胞（MiSOT）联盟第四次专家会议在巴塞罗那举行。本次会议重点关注将临床前数据转化为早期临床环境。本立场文件强调了在实体器官移植中作为治疗剂的间充质干细胞的安全性和有效性方面探索的主要主题，并强调了 MiSOT 联盟在未来研究中将要解决和跟进的问题（适当的时机、伴随免疫抑制、间充质干细胞的来源和免疫原性以及致癌性）。
相似文献
1
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.实体器官移植中的间充质干细胞（MiSOT）第四次会议：首次临床试验的经验教训。
Transplantation. 2013 Aug 15;96(3):234-8. doi: 10.1097/TP.0b013e318298f9fa.
2
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT).间质干细胞疗法在实体器官移植中的进展（MISOT）。
Transplantation. 2010 Jul 27;90(2):124-6. doi: 10.1097/TP.0b013e3181ea4240.
3
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group.迈向实体器官移植中的间充质干细胞：MISOT研究组2008年立场文件
Transplantation. 2009 Sep 15;88(5):614-9. doi: 10.1097/TP.0b013e3181b4425a.
4
Mesenchymal stem cells: application for solid-organ transplantation.间充质干细胞：在实体器官移植中的应用。
Curr Opin Organ Transplant. 2012 Feb;17(1):55-62. doi: 10.1097/MOT.0b013e32834ee676.
5
Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.肝移植后间充质基质细胞输注：I-II 期、开放性、临床研究。
J Hepatol. 2017 Jul;67(1):47-55. doi: 10.1016/j.jhep.2017.03.001. Epub 2017 Mar 9.
6
Japan's approval of stem-cell treatment for spinal-cord injury concerns scientists.日本批准用干细胞疗法治疗脊髓损伤引发了科学家们的担忧。
Nature. 2019 Jan;565(7741):544-545. doi: 10.1038/d41586-019-00178-x.
7
Caveats of mesenchymal stem cell therapy in solid organ transplantation.实体器官移植中间充质干细胞治疗的注意事项。
Transpl Int. 2015 Jan;28(1):1-9. doi: 10.1111/tri.12415. Epub 2014 Sep 30.
8
First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation.首例人体病例研究：肝移植后用于免疫调节的多能成人祖细胞
Stem Cells Transl Med. 2015 Aug;4(8):899-904. doi: 10.5966/sctm.2015-0002. Epub 2015 Jun 3.
9
A Brief Analysis of Mesenchymal Stem Cells as Biological Drugs for the Treatment of Acute-on-Chronic Liver Failure (ACLF): Safety and Potency.浅析间充质干细胞作为治疗慢加急性肝衰竭（ACLF）的生物药物的安全性和有效性。
Curr Stem Cell Res Ther. 2020;15(3):202-210. doi: 10.2174/1574888X15666200101124317.
10
Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation.间充质干细胞在实体器官移植中作为免疫疗法的潜力。
Transpl Int. 2009 Apr;22(4):365-76. doi: 10.1111/j.1432-2277.2008.00786.x. Epub 2008 Nov 1.
引用本文的文献
1
The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.基于间充质干细胞的先进治疗药品的异质性问题——综述
Front Cell Dev Biol. 2024 Jul 26;12:1400347. doi: 10.3389/fcell.2024.1400347. eCollection 2024.
2
Delivery of Mesenchymal Stem Cells during Hypothermic Machine Perfusion in a Translational Kidney Perfusion Study.在转化肾脏灌注研究中的低温机器灌注期间输送间充质干细胞。
Int J Mol Sci. 2024 May 5;25(9):5038. doi: 10.3390/ijms25095038.
3
The Immunomodulatory Properties of Mesenchymal Stem Cells Play a Critical Role in Inducing Immune Tolerance after Liver Transplantation.间充质干细胞的免疫调节特性在肝移植后诱导免疫耐受中起关键作用。
Stem Cells Int. 2021 Sep 4;2021:6930263. doi: 10.1155/2021/6930263. eCollection 2021.
4
Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes.大动物血管化复合组织同种异体移植模型：改善移植物结局的免疫策略综述。
Front Immunol. 2021 Jun 30;12:664577. doi: 10.3389/fimmu.2021.664577. eCollection 2021.
5
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).用于治疗新冠肺炎急性呼吸窘迫综合征（ARDS）患者的脐带间充质干细胞
CellR4 Repair Replace Regen Reprogram. 2020;8. doi: 10.32113/cellr4_20204_2839. Epub 2020 Apr 28.
6
Ex Vivo Mesenchymal Stem Cell Therapy to Regenerate Machine Perfused Organs.体外间充质干细胞疗法用于再生机器灌注器官。
Int J Mol Sci. 2021 May 15;22(10):5233. doi: 10.3390/ijms22105233.
7
Mesenchymal stromal cells for corneal transplantation: Literature review and suggestions for successful clinical trials.间质基质细胞用于角膜移植：文献综述及对成功临床试验的建议。
Ocul Surf. 2021 Apr;20:185-194. doi: 10.1016/j.jtos.2021.02.002. Epub 2021 Feb 16.
8
Immunomodulatory Properties of Mesenchymal Stromal Cells Can Vary in Genetically Modified Rats.基因修饰大鼠的间充质基质细胞的免疫调节特性可能存在差异。
Int J Mol Sci. 2021 Jan 25;22(3):1181. doi: 10.3390/ijms22031181.
9
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting.再生医学在器官移植中的出现：第 1 届欧洲细胞治疗和器官再生分会会议。
Transpl Int. 2020 Aug;33(8):833-840. doi: 10.1111/tri.13608. Epub 2020 Apr 28.
10
Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery.用于免疫治疗以及基因和药物递送的治疗性间充质基质细胞
Mol Ther Methods Clin Dev. 2020 Jan 22;16:204-224. doi: 10.1016/j.omtm.2020.01.005. eCollection 2020 Mar 13.
本文引用的文献
1
Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy.终末期肾病患者的骨髓间充质基质细胞适合自体治疗。
Cytotherapy. 2013 Jun;15(6):663-72. doi: 10.1016/j.jcyt.2013.01.010. Epub 2013 Feb 16.
2
Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.自体骨髓来源间充质基质细胞治疗肾移植后移植物排斥反应：Ⅰ期研究结果。
Stem Cells Transl Med. 2013 Feb;2(2):107-11. doi: 10.5966/sctm.2012-0114. Epub 2013 Jan 24.
3
Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study.供体来源间充质干细胞联合低剂量他克莫司预防肾移植后急性排斥反应：一项临床初步研究。
Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53.
4
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion.间充质干细胞寿命短，静脉输注后不会迁移到肺部以外的部位。
Front Immunol. 2012 Sep 26;3:297. doi: 10.3389/fimmu.2012.00297. eCollection 2012.
5
Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.欧洲的细胞治疗药物监管框架及其在 MSC 为基础的治疗开发中的应用。
Front Immunol. 2012 Aug 14;3:253. doi: 10.3389/fimmu.2012.00253. eCollection 2012.
6
Mesenchymal stromal cells: a key player in 'innate tolerance'?间质基质细胞：“先天耐受”的关键参与者？
Immunology. 2012 Nov;137(3):206-13. doi: 10.1111/j.1365-2567.2012.03621.x.
7
Mesenchymal stem cells derived from adipose tissue are not affected by renal disease.脂肪组织来源的间充质干细胞不受肾病影响。
Kidney Int. 2012 Oct;82(7):748-58. doi: 10.1038/ki.2012.187. Epub 2012 Jun 13.
8
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.自体间充质干细胞诱导治疗活体亲属肾移植：一项随机对照试验。
JAMA. 2012 Mar 21;307(11):1169-77. doi: 10.1001/jama.2012.316.
9
Multipotent mesenchymal stromal cell therapy and risk of malignancies.多能间充质基质细胞治疗与恶性肿瘤风险。
Stem Cell Rev Rep. 2013 Feb;9(1):65-79. doi: 10.1007/s12015-011-9345-4.
10
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).肝移植后免疫调节治疗中第三方多能成体祖细胞的安全性和可行性：一项 I 期研究（MISOT-I）。
J Transl Med. 2011 Jul 28;9:124. doi: 10.1186/1479-5876-9-124.
Zotero 插件